These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35077268)

  • 1. A stochastically curtailed single-arm phase II trial design for binary outcomes.
    Law M; Grayling MJ; Mander AP
    J Biopharm Stat; 2022 Sep; 32(5):671-691. PubMed ID: 35077268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A stochastically curtailed two-arm randomised phase II trial design for binary outcomes.
    Law M; Grayling MJ; Mander AP
    Pharm Stat; 2021 Mar; 20(2):212-228. PubMed ID: 32860470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards.
    Sharma P; Phadnis MA
    J Biopharm Stat; 2024 Jul; 34(4):596-611. PubMed ID: 37574976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stochastically curtailed phase II clinical trials.
    Ayanlowo AO; Redden DT
    Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.
    Bratton DJ; Phillips PP; Parmar MK
    BMC Med Res Methodol; 2013 Nov; 13():139. PubMed ID: 24229079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curtailed two-stage design for comparing two arms in randomized phase II clinical trials.
    Chen CM; Chi Y; Chang HM
    J Biopharm Stat; 2018; 28(5):939-950. PubMed ID: 29355457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-stage phase II oncology designs using short-term endpoints for early stopping.
    Kunz CU; Wason JM; Kieser M
    Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible designs for phase II comparative clinical trials involving two response variables.
    Bersimis S; Sachlas A; Papaioannou T
    Stat Med; 2015 Jan; 34(2):197-214. PubMed ID: 25274584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
    Richert L; Doussau A; Lelièvre JD; Arnold V; Rieux V; Bouakane A; Lévy Y; Chêne G; Thiébaut R;
    Trials; 2014 Feb; 15():68. PubMed ID: 24571662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.
    Waleed M; He J; Phadnis MA
    Pharm Stat; 2021 May; 20(3):610-644. PubMed ID: 33565236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian decision-theoretic sequential response-adaptive randomization design.
    Jiang F; Jack Lee J; Müller P
    Stat Med; 2013 May; 32(12):1975-94. PubMed ID: 23315678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized Bayesian optimal phase II design with binary endpoint.
    Ding Y
    J Biopharm Stat; 2023 Mar; 33(2):151-166. PubMed ID: 35793222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.